Joan BladÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4580208/publications.pdf

Version: 2024-02-01

232	18,893	44069 48	12272 133
papers	citations	h-index	g-index

236	236	236	11626
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	10.7	3,343
2	International Staging System for Multiple Myeloma. Journal of Clinical Oncology, 2005, 23, 3412-3420.	1.6	2,404
3	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
4	CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGHâ€DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION. British Journal of Haematology, 1998, 102, 1115-1123.	2.5	1,380
5	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	1.4	849
6	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet, The, 2016, 387, 1551-1560.	13.7	724
7	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology, The, 2014, 15, 1195-1206.	10.7	695
8	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, 2012, 120, 1589-1596.	1.4	429
9	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncology, The, 2010, 11, 934-941.	10.7	427
10	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood, 2014, 123, 3073-3079.	1.4	380
11	Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach. Journal of Clinical Oncology, 2011, 29, 3805-3812.	1.6	302
12	Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 395, 132-141.	13.7	299
13	High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood, 2005, 106, 3755-3759.	1.4	298
14	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 2011, 118, 4346-4352.	1.4	259
15	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology, 2017, 35, 2900-2910.	1.6	248
16	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematology,the, 2020, 7, e370-e380.	4.6	170
17	Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood, 2019, 134, 1337-1345.	1.4	148
18	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, BloodÂand Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146

#	Article	IF	Citations
19	Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 1992, 81, 391-394.	2.5	140
20	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
21	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood, 2016, 127, 3165-3174.	1.4	129
22	Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1127-1136.	10.7	128
23	Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood, 2010, 115, 3655-3663.	1.4	113
24	Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood, 2019, 134, 421-431.	1.4	110
25	Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations. Journal of Clinical Oncology, 2010, 28, 690-697.	1.6	101
26	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 757-767.	1.6	98
27	Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2006, 355, 2765-2770.	27.0	97
28	GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. Blood, 2014, 124, 1887-1893.	1.4	95
29	European Perspective on Multiple Myeloma Treatment Strategies in 2014. Oncologist, 2014, 19, 829-844.	3.7	90
30	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood, 2016, 127, 1896-1906.	1.4	81
31	Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica, 2017, 102, 1099-1104.	3.5	81
32	Transplantation for multiple myeloma: who, when, how often?. Blood, 2003, 102, 3469-3477.	1.4	76
33	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17.	6.2	75
34	Thalidomide in multiple myeloma: lack of response of softâ€tissue plasmacytomas. British Journal of Haematology, 2001, 113, 422-424.	2.5	73
35	Complications of Multiple Myeloma. Hematology/Oncology Clinics of North America, 2007, 21, 1231-1246.	2.2	71
36	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood, 2016, 127, 1151-1162.	1.4	68

#	Article	IF	Citations
37	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	7.2	68
38	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	7.1	67
39	Expert review on softâ€tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	2.5	67
40	Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood, 2014, 124, 2498-2506.	1.4	62
41	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	6.2	62
42	Renal, hematologic and infectious complications in multiple myeloma. Best Practice and Research in Clinical Haematology, 2005, 18, 635-652.	1.7	61
43	Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer Journal, 2022, 12, 45.	6.2	57
44	Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematology, 1994, 88, 117-121.	2.5	56
45	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. Blood, 2013, 122, 767-767.	1.4	56
46	Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. Clinical Lymphoma and Myeloma, 2008, 8, 352-355.	1.4	54
47	Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood, 2016, 127, 420-425.	1.4	51
48	Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood, 2015, 126, 858-862.	1.4	50
49	Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. The Hematology Journal, 2001, 2, 272-278.	1.4	50
50	Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Reviews, 2015, 29, 387-403.	5.7	48
51	Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia, 2018, 32, 1427-1434.	7.2	48
52	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica, 2020, 105, 201-208.	3.5	48
53	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncology, The, 2021, 22, 142-154.	10.7	46
54	The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. Haematologica, 2017, 102, 1776-1784.	3.5	43

#	Article	IF	Citations
55	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget, 2015, 6, 1874-1883.	1.8	42
56	Pyoderma Gangrenosum Triggered by Î±2b-Interferon in a Patient with Chronic Granulocytic Leukemia. Leukemia and Lymphoma, 1998, 30, 199-202.	1.3	41
57	Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine, 2008, 41, 244-253.	3.2	41
58	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer, 2016, 122, 2050-2056.	4.1	40
59	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3151-3161.	1.6	40
60	A new prognostic system for multiple myeloma based on easily available parameters. British Journal of Haematology, 1989, 72, 507-511.	2.5	39
61	Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 44-49.	0.4	38
62	A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. British Journal of Haematology, 2015, 170, 804-813.	2.5	38
63	Bortezomib: A valuable new antineoplastic strategy in multiple myeloma. Acta OncolÃ³gica, 2005, 44, 440-448.	1.8	35
64	Melflufen: A Peptideâ€“Drug Conjugate for the Treatment of Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 3120.	2.4	35
65	Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine, 2004, 26, 145-148.	3.2	34
66	How I treat relapsed myeloma. Blood, 2015, 125, 1532-1540.	1.4	31
67	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 4688-4698.	7.0	30
68	DEVELOPMENT OF AGGRESSIVE PLASMA CELL LEUKAEMIA UNDER INTERFERON-ALPHA THERAPY. British Journal of Haematology, 1991, 79, 523-525.	2.5	29
69	Advances in therapy of multiple myeloma. Current Opinion in Oncology, 2008, 20, 697-704.	2.4	29
70	An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. Blood, 2014, 124, 176-176.	1.4	27
71	Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for lightâ€chain deposition disease. European Journal of Haematology, 2012, 89, 340-344.	2.2	26
72	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia, 2020, 34, 3007-3018.	7.2	26

#	Article	IF	Citations
73	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood, 2020, 135, 2375-2387.	1.4	24
74	Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)aì,/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadeaì, as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.. Blood, 2009, 114, 130-130.	1.4	24
75	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. Blood, 2021, 138, 1901-1905.	1.4	23
76	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 785-798.	0.4	22
77	Extramedullary disease in multiple myeloma in the era of novel agents. British Journal of Haematology, 2015, 169, 763-765.	2.5	21
78	Pomalidomideâ€dexamethasone for treatment of softâ€tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. European Journal of Haematology, 2019, 102, 389-394.	2.2	21
79	Aminoglycoside-associated Severe Renal Failure in Patients with Multiple Myeloma Treated with Thalidomide. Leukemia and Lymphoma, 2004, 45, 1711-1712.	1.3	20
80	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e493-e499.	0.4	20
81	Complement as the enabler of carfilzomibâ€induced thrombotic microangiopathy. British Journal of Haematology, 2021, 193, 181-187.	2.5	20
82	Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. Journal of Immunology, 2018, 200, 2581-2591.	0.8	19
83	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Advances, 2022, 6, 690-703.	5.2	19
84	A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib. Blood, 2010, 116, 307-307.	1.4	19
85	Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica, 2022, 107, 2408-2417.	3.5	19
86	CYTOKINE THERAPY IN MULTIPLE MYELOMA*. British Journal of Haematology, 1996, 94, 425-432.	2.5	18
87	A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica, 2018, 103, 1518-1526.	3.5	18
88	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica, 2019, 104, 2358-2360.	3.5	18
89	The renal range of the Î°/Î» sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease. BMC Nephrology, 2020, 21, 111.	1.8	18
90	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. Blood, 2009, 114, 2878-2878.	1.4	18

#	Article	IF	Citations
91	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148.		17
92	Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. Leukemia Research, 2013, 37, 641-646.	0.8	17
93	Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e71-e77.	0.4	17
94	Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 79-85.	3.0	17
95	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 190, 346-357.	2.5	17
96	Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3245-3245.	1.4	17
97	A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2006, 108, 795-795.	1.4	17
98	Phase II study of daratumumab (DARA) monotherapy in patients with â‰¥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. Journal of Clinical Oncology, 2015, 33, LBA8512-LBA8512.	1.6	17
99	First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. , 2021, 9, e003783.		17
100	Cross-resistance to alkylating agents in multiple myeloma. Cancer, 1983, 52, 786-789.	4.1	15
101	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. Blood Advances, 2020, 4, 6023-6033.	5.2	15
102	Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.. Journal of Clinical Oncology, 2019, 37, 8005-8005.	1.6	15
103	Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS).. Journal of Clinical Oncology, 2020, 38, 8512-8512.	1.6	15
104	Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Current Treatment Options in Oncology, 2006, 7, 237-245.	3.0	14
105	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer Journal, 2021, 11, 101.	6.2	14
106	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update. Blood, 2019, 134, 1865-1865.	1.4	14
107	Antimyeloma Efficacy of Plitidepsin (AplidinÂ®): From Bench to the Bedside.. Blood, 2007, 110, 1178-1178.	1.4	14
108	A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.. Blood, 2009, 114, 3-3.	1.4	13

#	Article	IF	Citations
109	Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8018-8018.	1.6	13
110	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. American Journal of Hematology, 2022, , .	4.1	13
111	Extramedullary Myeloma Spread Triggered by Surgical Procedures: An Emerging Entity?. Acta Haematologica, 2014, 132, 36-38.	1.4	12
112	Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leukemia Research Reports, 2015, 4, 64-69.	0.4	12
113	A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. Haematologica, 2018, 103, 880-889.	3.5	12
114	Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study. Blood, 2015, 126, 721-721.	1.4	12
115	Risk of relapse and clinicoâ€pathological features in 103 patients with diffuse largeâ€cell lymphoma in complete response after firstâ€line treatment. European Journal of Haematology, 1998, 61, 59-64.	2.2	11
116	Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2017, 179, 849-851.	2.5	11
117	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. Blood, 2019, 133, 2664-2668.	1.4	11
118	Supportive Care in AL Amyloidosis. Acta Haematologica, 2020, 143, 335-342.	1.4	11
119	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. Cancers, 2021, 13, 4924.	3.7	11
120	A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.. Blood, 2009, 114, 3852-3852.	1.4	11
121	Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.. Journal of Clinical Oncology, 2018, 36, 8002-8002.	1.6	11
122	Efficacy and Safety of Re-Treatment with Bortezomib (VelcadeÂ©) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial. Blood, 2008, 112, 3690-3690.	1.4	10
123	High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM). Blood, 2016, 128, 482-482.	1.4	10
124	Multiple Myeloma Following Essential Thrombocythemia. Leukemia and Lymphoma, 1995, 20, 177-179.	1.3	9
125	Are all myelomas preceded by MGUS?. Blood, 2009, 113, 5370-5370.	1.4	9
126	Response evaluation and monitoring of multiple myeloma. Expert Review of Hematology, 2014, 7, 33-42.	2.2	8

#	Article	IF	Citations
127	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. Leukemia, 2018, 32, 2427-2434.	7.2	8
128	Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project. BMJ Open, 2018, 8, e018850.	1.9	8
129	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Advances in Therapy, 2020, 37, 1464-1478.	2.9	8
130	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1â€acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. British Journal of Haematology, 2021, 192, 522-530.	2.5	8
131	Treatment of Patients with Monoclonal Gammopathy of Clinical Significance. Cancers, 2021, 13, 5131.	3.7	8
132	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 68.	6.2	8
133	Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2002, 117, 387-389.	2.5	7
134	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. Cancers, 2020, 12, 3615.	3.7	7
135	Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. Blood Advances, 2021, 5, 1340-1343.	5.2	7
136	Patientâ€reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. British Journal of Haematology, 2022, 196, 639-648.	2.5	7
137	Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin.. Blood, 2009, 114, 109-109.	1.4	7
138	Competition Between (Mono)Clonal Plasma Cells and Normal Cells for Potentially Overlapping Bone Marrow Niches Is Associated with a Progressively Altered Cellular Distribution In MGUS Vs. Myeloma. Blood, 2010, 116, 617-617.	1.4	7
139	Refining â€œtotal therapyâ€• for myeloma. Blood, 2010, 115, 4152-4153.	1.4	6
140	M-proteinâ€“related disorders: MGCS. Blood, 2018, 132, 1464-1465.	1.4	6
141	Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplantation, 2019, 54, 1295-1303.	2.4	6
142	Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 413-420.	0.4	6
143	Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 3700-3700.	1.4	6
144	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. Blood, 2009, 114, 743-743.	1.4	6

#	Article	IF	Citations
145	A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,. Blood, 2011, 118, 3962-3962.	1.4	6
146	Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience. Blood, 2014, 124, 3460-3460.	1.4	6
147	Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival. Blood, 2014, 124, 3465-3465.	1.4	6
148	Realâ€world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45â€year period. British Journal of Haematology, 2022, 196, 649-659.	2.5	6
149	The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 5190-5190.	1.4	6
150	An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. Stem Cells, 1995, 13, 122-125.	3.2	5
151	Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. Annals of Hematology, 2014, 93, 107-111.	1.8	5
152	Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 238-245.	3.0	5
153	Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma. British Journal of Haematology, 2021, 193, 299-306.	2.5	5
154	Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy. Cancers, 2021, 13, 2055.	3.7	5
155	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba. Blood, 2019, 134, 1906-1906.	1.4	5
156	Efficacy and Safety of Retreatment with Bortezomib in Patients with Multiple Myeloma: Interim Results From RETRIEVE, a Prospective International Phase 2 Study.. Blood, 2009, 114, 3866-3866.	1.4	5
157	HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).. Journal of Clinical Oncology, 2020, 38, e20570-e20570.	1.6	5
158	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS ONE, 2020, 15, e0241778.	2.5	5
159	Why Immunotherapy Fails in Multiple Myeloma. Hemato, 2021, 2, 1-42.	0.6	5
160	Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer Journal, 2022, 12, 76.	6.2	5
161	Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases. American Journal of Kidney Diseases, 2021, 78, 755-759.	1.9	4
162	Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination. Blood, 2010, 116, 309-309.	1.4	4

#	Article	IF	Citations
163	Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. Blood, 2013, 122, 403-403.	1.4	4
164	Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial. Blood, 2014, 124, 3390-3390.	1.4	4
165	Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials. Blood, 2015, 126, 19-19.	1.4	4
166	Phase II study of daratumumab (DARA) monotherapy in patients with â‰¥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. Journal of Clinical Oncology, 2015, 33, LBA8512-LBA8512.	1.6	4
167	Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2017, 23, 1269-1275.	2.0	3
168	Tratamiento del mieloma mÃºltiple asintomÃ¡tico: recomendaciones del Grupo EspaÃ±ol de Mieloma. Medicina ClÃnica, 2017, 148, 517-523.	0.6	3
169	Testicular plasmacytoma: unique location or circumstantial presentation?. Leukemia and Lymphoma, 2018, 59, 1769-1771.	1.3	3
170	Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma: Results of a PETHEMA Phase II Trial.. Blood, 2006, 108, 3086-3086.	1.4	3
171	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Frontiers in Immunology, 2021, 12, 792609.	4.8	3
172	Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma. Frontiers in Oncology, 0, 12, .	2.8	3
173	Toward deeper response in MM. Blood, 2011, 117, 2986-2987.	1.4	2
174	Monoclonal gammopathy of undetermined significance: a contraindication for living kidney donation?. CKJ: Clinical Kidney Journal, 2011, 4, 256-257.	2.9	2
175	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Annals of Hematology, 2021, 100, 2997-3005.	1.8	2
176	Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets. Blood, 2019, 134, 4355-4355.	1.4	2
177	Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance. Blood, 2020, 136, 5-6.	1.4	2
178	Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials. Blood, 2010, 116, 1910-1910.	1.4	2
179	Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,. Blood, 2011, 118, 3938-3938.	1.4	2
180	Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years. Blood, 2015, 126, 1848-1848.	1.4	2

#	Article	IF	Citations
181	Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH). Blood, 2015, 126, 4243-4243.	1.4	2
182	Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. Blood, 2016, 128, 3283-3283.	1.4	2
183	Prognostic value of deep sequencing method for minimal residual disease (MRD) detection in multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8511-8511.	1.6	2
184	Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).. Journal of Clinical Oncology, 2018, 36, e20024-e20024.	1.6	2
185	Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance. Blood, 2014, 124, 25-25.	1.4	2
186	The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients. Blood, 2015, 126, 4181-4181.	1.4	2
187	Autologous transplantation in multiple myeloma. Haematologica, 2006, 91, 1157.	3.5	2
188	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Therapeutic Advances in Hematology, 2022, 13, 204062072210884.	2.5	2
189	Issues of front-line therapy for multiple myeloma â€“ the standard of care. Leukemia and Lymphoma, 2014, 55, 1959-1961.	1.3	1
190	The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor. Leukemia, 2018, 32, 2082-2094.	7.2	1
191	Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.. Journal of Clinical Oncology, 2021, 39, 8048-8048.	1.6	1
192	Management of patients with difficult-to-treat multiple myeloma. Future Oncology, 2021, 17, 2089-2105.	2.4	1
193	OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma.. Blood, 2009, 114, 959-959.	1.4	1
194	Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients,. Blood, 2011, 118, 3936-3936.	1.4	1
195	Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression. Blood, 2013, 122, 1973-1973.	1.4	1
196	Tumor and Renal Response in Patients with Newly Diagnosed Multiple Mieloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM. Blood, 2014, 124, 4776-4776.	1.4	1
197	Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials. Blood, 2015, 126, 2962-2962.	1.4	1
198	What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity. Blood, 2015, 126, 725-725.	1.4	1

#	Article	IF	Citations
199	Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM). Blood, 2016, 128, 373-373.	1.4	1
200	Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.. Blood, 2007, 110, 729-729.	1.4	1
201	The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 5192-5192.	1.4	1
202	Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation.. Blood, 2009, 114, 1811-1811.	1.4	1
203	Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients. Blood, 2010, 116, 2394-2394.	1.4	1
204	Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),. Blood, 2011, 118, 3951-3951.	1.4	1
205	Myelodysplasia-Associated Immunophenotypic Abnormalities of Bone Marrow (BM) Cells in Multiple Myeloma (MM): Are They Present At Diagnosis or Can Be Induced by Lenalidomide?. Blood, 2011, 118, 5066-5066.	1.4	1
206	Phase II Optimization, Open-Label Clinical Trial of ZalypsisÂ® (PM00104) in Relapsed/Refractory Multiple Myeloma Patients. Blood, 2012, 120, 4041-4041.	1.4	1
207	Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM). Blood, 2013, 122, 3188-3188.	1.4	1
208	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. Blood, 2016, 128, 375-375.	1.4	1
209	Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic. Blood, 2021, 138, 2719-2719.	1.4	1
210	Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?. Seminars in Oncology, 2003, 30, 329-331.	2.2	0
211	SMM: toward better predictors of progression. Blood, 2008, 111, 479-480.	1.4	0
212	IMPACT OF RENAL FUNCTION ON THE MYELOMA STAGING. Scandinavian Journal of Haematology, 1984, 33, 399-400.	0.0	0
213	Six-2 glomerular expression for the prediction of renal outcome in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 97-98.	3.0	0
214	Effect of Pre and Post-Transplantation Responses on Outcome of Multiple Myeloma Patients: CR and near-CR Should Not Be Considered as Equivalent Prognostic Markers. Results of a PETHEMA/Gem Prospective Study. Blood, 2008, 112, 161-161.	1.4	0
215	Influence of Genetic Polymorphisms in CYP1A2, CYP2C19, CYP3A4, GSTP1, MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More). Blood, 2011, 118, 1412-1412.	1.4	0
216	Influence of Lenalidomide Treatment on Immune Effector Cells From High-Risk Smoldering Multiple Myeloma (SMM) Patients,. Blood, 2011, 118, 3944-3944.	1.4	0

#	Article	IF	Citations
217	High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM). Blood, 2011, 118, 630-630.	1.4	0
218	Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.. Journal of Clinical Oncology, 2013, 31, 8544-8544.	1.6	0
219	Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution. Blood, 2013, 122, 3132-3132.	1.4	0
220	Phenotypic Identification Of Subclones In Multiple Myeloma With Different Genomic Profile, Clonogenic Potential and Drug Sensitivity. Blood, 2013, 122, 531-531.	1.4	0
221	Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs). Blood, 2013, 122, 402-402.	1.4	0
222	Allogeneic Stem-Sell Transplantation In Multiple Myeloma In Real Practice: Long-Term Results From a Single Institution. Blood, 2013, 122, 5524-5524.	1.4	0
223	Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients. Blood, 2013, 122, 1848-1848.	1.4	0
224	Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CYCLO-LEN-DEX) for Previously Untreated Patients with Light-Chain Amyloidosis (AL). Blood, 2014, 124, 2135-2135.	1.4	0
225	Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens. Blood, 2014, 124, 2108-2108.	1.4	0
226	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. Blood, 2015, 126, 3049-3049.	1.4	0
227	Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Blood, 2015, 126, 2963-2963.	1.4	0
228	Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status. Blood, 2015, 126, 4192-4192.	1.4	0
229	Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients. Blood, 2015, 126, 2955-2955.	1.4	0
230	BET Bromodomain Blockade Enhances Ikaros Inhibition By Lenalidomide Therapy Providing Additional Activity in In Vitro and In Vivo Models of Multiple Myeloma. Blood, 2016, 128, 308-308.	1.4	0
231	Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma. Blood, 2020, 136, 5-6.	1.4	0
232	Thalidomide and dexamethasone in patients with multiple myeloma not undergoing upfront autologous stem cell transplantation. Haematologica, 2005, 90, 1589.	3.5	0